NewsRx

Search our medical news database

Pathogenesis (HIV)

"EBV-Specific T-Cell Immunity in AIDS Related NonHodgkin's Lymphoma."

Published in Cancer Weekly, April 22nd, 1996

According to an abstract submitted by the authors to the 37th Annual Meeting of the American Society of Hematology, held December 1-5, 1995, in Seattle, Washington, "The vast majority of AIDS-NHL are diffuse large-cell and immunoblastic lymphomas, thought to arise because of uncontrolled EBV-driven proliferation of B cells. Although EBV-specific CD8+ MHC class I-restricted cytotoxic T lymphocytes (CTL) are known to play a key role in EBV-specific immunity in healthy individuals, the mechanism of the defective EBV-immunosurveillance in HIV infection is largely unknown. The present study is aimed at two questions: 1) What is the temporal relationship between EBV-specific...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook